Abstract
Despite their limited licensed indications, anti-IL1 agents are often used in real-life practice for an increasing number of diseases. A national survey to record the off-label use of this class of therapeutics in France was started in January 2011. The survey is coordinated by the French National Reference Centre for Auto-inflammatory Diseases, under the aegis of the Club Rhumatisme et Inflammation.
Highlights
Despite their limited licensed indications, anti-IL1 agents are often used in real-life practice for an increasing number of diseases
A complete physician-evaluated response was reported in Schnitzler’s syndrome (85%), gout (80%), CAPS (75%), adult onset Still disease (AoSD) (59%), familial Mediterranean fever (FMF) (50%), systemic onset juvenile idiopathic arthritis (SoJIA) (42%), mevalonate kinase deficiency (MKD) (30%), SAPHO (11%). 83% of canakinumab-treated patients showed clinical response
Main diseases were: adult onset Still disease (AoSD) (35), systemic onset juvenile idiopathic arthritis (SoJIA) (29), gout (27), anakinra-treated CAPS (22), mevalonate kinase deficiency (MKD) (14), 1Department of Paediatrics and Paediatric Rheumatology, Hôpital de Bicêtre, National Reference Centre for Auto-inflammatory Diseases, Le Kremlin Bicêtre, France Full list of author information is available at the end of the article
Summary
Despite their limited licensed indications, anti-IL1 agents are often used in real-life practice for an increasing number of diseases. A national survey to record the off-label use of this class of therapeutics in France was started in January 2011. The survey is coordinated by the French National Reference Centre for Auto-inflammatory Diseases, under the aegis of the “Club Rhumatisme et Inflammation”
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
